Thomas Danne, EASD 2019: Sotagliflozin in type 1 diabetes
At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Thomas Danne discusses his session on the latest clinical evidence supporting the use of sotagliflozin in type 1 diabetes.
Questions
1. What is the rationale for the use of sotagliflozin in as an adjunct to insulin therapy in type 1 diabetes (T1D)? (0:05)
2. What clinical evidence supports the use of sotagliflozin in T1D? (1:00)
3. What is the effect of sotagliflozin on the risk of diabetic ketoacidosis and urinary tract infections? (1:57)
4. Which patients are most likely to benefit from this treatment? (2:58)
5. What further research is needed before this treatment enters routine clinical use?
Thomas Danne has no conflicts of interest to declare in relation to this video.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.